Scinovex
review Open AccessTop 1% cited

Diabetes, Hypertension, and Cardiovascular Disease

Hypertension · 2001 · Vol. 37(4) · pp. 1053–1059
James R. SowersMurray EpsteinEdward D. Fröhlich

Abstract

Cardiovascular diseases (CVDs) are the major causes of mortality in persons with diabetes, and many factors, including hypertension, contribute to this high prevalence of CVD. Hypertension is approximately twice as frequent in patients with diabetes compared with patients without the disease. Conversely, recent data suggest that hypertensive persons are more predisposed to the development of diabetes than are normotensive persons. Furthermore, up to 75% of CVD in diabetes may be attributable to hypertension, leading to recommendations for more aggressive treatment (ie, reducing blood pressure to <130/85 mm Hg) in persons with coexistent diabetes and hypertension. Other important risk factors for CVD in these patients include the following: obesity, atherosclerosis, dyslipidemia, microalbuminuria, endothelial dysfunction, platelet hyperaggregability, coagulation abnormalities, and "diabetic cardiomyopathy." The cardiomyopathy associated with diabetes is a unique myopathic state that appears to be independent of macrovascular/microvascular disease and contributes significantly to CVD morbidity and mortality in diabetic patients, especially those with coexistent hypertension. This update reviews the current knowledge regarding these risk factors and their treatment, with special emphasis on the cardiometabolic syndrome, hypertension, microalbuminuria, and diabetic cardiomyopathy. This update also examines the role of the renin-angiotensin system in the increased risk for CVD in diabetic patients and the impact of interrupting this system on the development of clinical diabetes as well as CVD.

Blood Pressure and Hypertension StudiesDiabetes Treatment and ManagementPharmacology and Obesity TreatmentMedicineDiabetes mellitusMicroalbuminuriaDyslipidemiaInternal medicineDiabetic cardiomyopathyBlood pressureDiseaseCardiomyopathyCardiology

MeSH terms

AlbuminuriaAntihypertensive AgentsCardiovascular DiseasesDiabetic AngiopathiesHumansHypertensionRenin-Angiotensin SystemRisk FactorsControlled Clinical Trials as Topic

Funding

  • National Institutes of Health
Citations
1,336
FWCI
31.53
field-weighted impact
References
68
Percentile
100%
vs. same field & year
Citations per year
Cited by
Insulin resistance in chronic kidney disease: a systematic review
American Journal of Physiology-Renal Physiology · 2016 · 423 citations
Insulin resistance and hypertension
American Journal of Physiology-Heart and Circulatory Physiology · 2004 · 467 citations
Role of changes in cardiac metabolism in development of diabetic cardiomyopathy
American Journal of Physiology-Heart and Circulatory Physiology · 2006 · 447 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.